Colorectal cancer
GtoPdb Disease Summaries
This section gives an overview of the disease, and where available shows the following:
- Synonyms: Shows known synonyms for the disease.
- Description: Gives a basic description/definition of the disease.
- Database Link: External links to the same disease at the Disease Ontology, OMIM or Orphanet sites.
- Immunopharmacology comments: General comments about the target's role in immunopharmacology, provided by GtoImmuPdb curators.
- Associated with: Counts are displayed for the total targets the disease is associated with in GtoPdb. The counts of targets and ligands of immunological relevance associated to the disease are also shown.
More information can be found in the help pages.
✖| Disease ID: | 233 | |
| Name: | Colorectal cancer | |
| Associated with: | 18 targets | |
Targets
GtoPdb Disease Summaries - Targets
Click on the target name to link to its detailed view page
Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.
If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page
Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.
More information can be found in the help pages.
✖| CXCR5 | |
| References: | 5,9 |
| FZD7 | |
| References: | 4,12 |
| PKR1 | |
| References: | 7 |
| Mutations: | PKR1 is associated with 8 mutation. Click here for details  |
| Peroxisome proliferator-activated receptor-γ | |
| Comments: | Human colon cancer is associated with loss-of function mutations in PPAR-gamma ligand-binding domain, potential antitumor efficacity of combining RXR and PPAR-gamma agonist |
| References: | 1,3,10-11 |
| Ornithine decarboxylase | |
| Role: | A polymorphism in ODC1 is associated with reduced risk of colonic adenoma recurrence. |
| References: | 14 |
| sPLA2-2A |
| AKT serine/threonine kinase 1 |
| TLR2 |
| TLR3 |
| TLR4 |
| NLRP6 |
| aurora kinase A |
| B-Raf proto-oncogene, serine/threonine kinase | |
| Mutations: | B-Raf proto-oncogene, serine/threonine kinase is associated with 1 mutation. Click here for details |
| phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| E1A binding protein p300 |
| regulator of G-protein signaling 16 | |
| References: | 6 |
| regulator of G-protein signaling 12 | |
| Comments: | Colorectal tumors with high microsatellite instability |
| References: | 8,13 |
| NRAS |
Ligands
GtoPdb Disease Summaries - Ligands
Click ligand name to view ligand summary page
- Approved: If the ligand is an approved drug this is indicated, along with approval bodies.
- Immuno: Immuno icon indicates the ligand is immuno-relevant
Click the arrow in the final column to expand comments
- Immuno Disease Comments: Curatorial comments specifically added as part of GtoImmuPdb. They give more information on the association between the ligand and disease in the context of immunopharmacology.
- Clinical Use: General clinical comments relating to the ligand and may not necessarily be specific to the disease in question. With hyperlink to more details on the ligand summary pages.
- Bioactivty Comments: Curatorial comments specifically about the compounds biological activity - with hyperlink to more details on the ligand summary pages.
More information can be found in the help pages.
✖No ligand related data available for Colorectal cancer
References
1. Cesario RM, Stone J, Yen WC, Bissonnette RP, Lamph WW. (2006) Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer. Cancer Lett, 240 (2): 225-33. [PMID:16271436]
2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W et al.. (2002) Mutations of the BRAF gene in human cancer. Nature, 417 (6892): 949-54. [PMID:12068308]
3. Kim E, Chen F, Wang CC, Harrison LE. (2006) CDK5 is a novel regulatory protein in PPARgamma ligand-induced antiproliferation. Int J Oncol, 28 (1): 191-4. [PMID:16327995]
4. King TD, Zhang W, Suto MJ, Li Y. (2012) Frizzled7 as an emerging target for cancer therapy. Cell Signal, 24 (4): 846-51. [PMID:22182510]
5. Meijer J, Zeelenberg IS, Sipos B, Roos E. (2006) The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. Cancer Res, 66 (19): 9576-82. [PMID:17018614]
6. Miyoshi N, Ishii H, Sekimoto M, Doki Y, Mori M. (2009) RGS16 is a marker for prognosis in colorectal cancer. Ann Surg Oncol, 16 (12): 3507-14. [PMID:19760045]
7. O'Hayre M, Vázquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S, Gutkind JS. (2013) The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer, 13 (6): 412-24. [PMID:23640210]
8. Potocnik U, Glavac D, Ravnik-Glavac M. (2003) Identification of novel genes with somatic frameshift mutations within coding mononucleotide repeats in colorectal tumors with high microsatellite instability. Genes Chromosomes Cancer, 36 (1): 48-56. [PMID:12461749]
9. Qi XW, Xia SH, Yin Y, Jin LF, Pu Y, Hua D, Wu HR. (2014) Expression features of CXCR5 and its ligand, CXCL13 associated with poor prognosis of advanced colorectal cancer. Eur Rev Med Pharmacol Sci, 18 (13): 1916-24. [PMID:25010623]
10. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, de la Chapelle A, Spiegelman BM, Eng C. (1999) Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell, 3 (6): 799-804. [PMID:10394368]
11. Sasaki T, Fujii K, Yoshida K, Shimura H, Sasahira T, Ohmori H, Kuniyasu H. (2006) Peritoneal metastasis inhibition by linoleic acid with activation of PPARgamma in human gastrointestinal cancer cells. Virchows Arch, 448 (4): 422-7. [PMID:16362414]
12. Ueno K, Hiura M, Suehiro Y, Hazama S, Hirata H, Oka M, Imai K, Dahiya R, Hinoda Y. (2008) Frizzled-7 as a potential therapeutic target in colorectal cancer. Neoplasia, 10 (7): 697-705. [PMID:18592008]
13. Williams DS, Bird MJ, Jorissen RN, Yu YL, Walker F, Walker F, Zhang HH, Nice EC, Burgess AW. (2010) Nonsense mediated decay resistant mutations are a source of expressed mutant proteins in colon cancer cell lines with microsatellite instability. PLoS ONE, 5 (12): e16012. [PMID:21209843]
14. Zell JA, Ziogas A, Ignatenko N, Honda J, Qu N, Bobbs AS, Neuhausen SL, Gerner EW, Anton-Culver H. (2009) Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival. Clin Cancer Res, 15 (19): 6208-16. [PMID:19789310]
